ArticleMolecular medicine reports2018
Effect of prehypertensive losartan therapy on AT1R and ATRAP methylation of adipose tissue in the later life of high‑fat‑fed spontaneously hypertensive rats.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?Life (Basel, Switzerland) · 2023Review
- Summary of Known Genetic and Epigenetic Modification Contributed to Hypertension.International journal of hypertension · 2023Review
- Estrogen normalizes maternal HFD-induced vascular dysfunction in offspring by regulating ATR.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Anti-Inflammatory Effects of Ang-(1-7) Bone-Targeting Conjugate in an Adjuvant-Induced Arthritis Rat Model.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Bone-Targeted Delivery of Novokinin as an Alternative Treatment Option for Rheumatoid Arthritis.Pharmaceutics · 2022Article
- Article
- DNA Methylation of the Angiotensinogen Gene,International journal of molecular sciences · 2021Review
- ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?Journal of translational internal medicine · 2021Article
- Epigenetic modifications of the renin-angiotensin system in cardiometabolic diseases.Clinical science (London, England : 1979) · 2021Review
- Losartan does not inhibit cigarette smoke-induced lung inflammation in mice.Scientific reports · 2019Article
- Beneficial Cardiovascular Effects of Hydroalcoholic Extract from Crocus Sativus in Hypertension Induced by Angiotensin II.Journal of pharmacopuncture · 2019Article
- Early consumption of high-fat diet worsens renal damage in spontaneously hypertensive rats in adulthood.International journal of physiology, pathophysiology and pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is frequently associated with metabolic disorders. The present study was designed to investigate the long‑term effect of prehypertensive losartan therapy on metabolic disorders in high‑fat‑fed spontaneously hypertensive rats (SHRs), and to examine the role of epigenetic regulation of angiotensin II type 1 receptor (AT1R) and AT1 receptor‑associated protein (ATRAP) expression in adipose tissue. A total of 32 4‑week‑old male SHRs were divided into four groups (n=8 rats/group): Standard chow; standard chow + losartan; high‑fat diet; and high‑fat diet + losartan. At 10 weeks of age, treatment with losartan was discontinued. Rats were followed up until 26 weeks of age. Obesity, dyslipidemia, hyperglycemia, abnormal adipokine secretion, larger adipocytes and decreased expression of markers of adipocyte differentiation were present in high‑fat‑fed SHRs, and were attenuated in losartan‑treated rats. The increased expression and promoter hypomethylation of AT1R subtype a (AT1aR) in the adipose tissue of high‑fat‑fed SHRs were reversed by treatment with losartan. No difference was observed in the expression and promoter methylation of AT1R subtype b (AT1bR) among the four groups. Decreased expression and promoter hypermethylation of ATRAP were demonstrated in the adipose tissue of high‑fat‑fed SHRs. However, losartan made no difference to the expression and promoter methylation of ATRAP. Prehypertensive losartan therapy may relieve metabolic disorders in the later life of high‑fat‑fed SHRs. Differential epigenetic regulation of AT1aR and ATRAP expression through DNA methylation in adipose tissue may be involved in the long‑term beneficial effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.